Global healthcare giant Haleon has announced a £65 million ($86 million) investment to establish a cutting-edge oral health manufacturing facility in Shanghai, capitalizing on opportunities created by China's 15th Five-Year Plan (2026–2030). This strategic move comes as foreign enterprises align with the Chinese mainland's focus on high-quality development and domestic consumption growth.
The new facility targets surging demand in tier-2 and tier-3 cities, where rising disposable incomes and increased health awareness are driving consumers toward premium products. "Our investment reflects long-term confidence in China's health innovation landscape," said Haleon CEO Brian McNamara, emphasizing alignment with national priorities for economic resilience.
Analysts note the investment underscores broader trends in Asia's healthcare market, projected to grow 8.2% annually through 2030. The Chinese mainland's emphasis on technological upgrading and consumption-driven growth continues to attract global businesses seeking to expand in Asia's largest economy.
